Check access to the full text by signing in through your organization. • Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment–preliminary report • Hysteroscopic myomectomy: The guidelines of the International Society for Gynecologic Endoscopy (ISGE) There are more references available in the full text version of this article. © 2026 Published by Elsevier Inc. on behalf of AAGL.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by S’ Reply
Letter to the Editor Authors’ Reply
Authors’ Reply Author links open overlay panelEttore Cicinelli M.D., Ph.D. , Pierpaolo Nicolì M.D., Amerigo Vitagliano M.D., Ph.D. Show more Access through your organization Check access to the full text by signing in through your organization. Access through your organization Section snippets References 1. Cicinelli E, Nicolì P, De Vree BP, Vimercati A, Favilli A, Vitagliano A.
Authors’ Reply
Available online 11 May 2024 Letter to the Editor Authors’ Reply Author links open overlay panelHale Goksever Celik M.D., Assoc. Prof. 1 , Ercan Bastu M.D., Prof. 2 Show more HG Celik et al. J Minim Invasive Gynecol (2023) S Lau et al. Fertil Steril (1999) There are more references available in the full text version of this article. View full text © 2024 Published by Elsevier Inc. on behalf of AAGL.
Authors’ Reply
In order to get access to the article, you must have an account. If you have an account, enter your user name and password into the boxes above. If you do not have an account, follow the instructions below to create one. Once you have purchased the article, you will have access to it for 24 hours. Steps for Creating an Account: Click the "Purchase Access" button. The page will redisplay with the following message at the top of the screen. In the message, click to create an account.
Authors’ Reply
Authors’ Reply Andrew J.B. Watts, Keith H. Keller, Astrid Weins JASN Mar 2022, 33 (3) 654; DOI: 10.1681/ASN.2021121540
Authors’ Reply
In order to get access to the article, you must have an account. If you have an account, enter your user name and password into the boxes above. If you do not have an account, follow the instructions below to create one. Once you have purchased the article, you will have access to it for 24 hours. Steps for Creating an Account: Click the "Purchase Access" button. The page will redisplay with the following message at the top of the screen. In the message, click to create an account.
Authors’ Reply
Authors’ Reply Andrew J.B. Watts, Keith H. Keller, Astrid Weins JASN Jan 2022, ASN.2021121540; DOI: 10.1681/ASN.2021121540
Authors’ Reply
acute rejection acute allograft rejection chronic allograft rejection kidney kidney biopsy transplantation We thank Drs. Gupta and Kaplan for their insightful comments. As we noted in our Research Letter, this preliminary report of the novel two-threshold algorithm had a small cohort size and limited confirmatory biopsy specimen data.1 We are currently in the process of applying this two-threshold algorithm to a larger cohort as part of a prospective, >30-site study with full biopsy matching.
Authors’ Reply
renal fibrosis We appreciate Liu and Zhang’s interest in our recent study. We agree that, given previous studies by Lassen et al.1 and Lorenz et al.,2 our findings that selective myeloid deletion of interferon regulatory factor 4 (IRF4) decreased development of tubulointerstitial fibrosis3 after ischemic kidney injury were somewhat unexpected. However, there are two crucial differences between our study and the two previous studies.
Authors’ Reply
acute renal failure pediatric nephrology children chronic kidney disease We thank Zhao et al.1 and Wei2 for their interest in our manuscript, “Long-term kidney outcomes following childhood acute kidney injury receiving dialysis: A population-based cohort study,”3 and for providing thoughtful feedback. The letter from Zhao et al.1 correctly highlights that outcomes after AKI differ significantly depending on the cause of AKI.
Authors’ Reply
renal fibrosis We appreciate Liu and Zhang’s interest in our recent study. We agree that, given previous studies by Lassen et al.1 and Lorenz et al.,2 our findings that selective myeloid deletion of interferon regulatory factor 4 (IRF4) decreased development of tubulointerstitial fibrosis3 after ischemic kidney injury were somewhat unexpected. However, there are two crucial differences between our study and the two previous studies.
Authors’ Reply
acute renal failure pediatric nephrology children chronic kidney disease We thank Zhao et al.1 and Wei2 for their interest in our manuscript, “Long-term kidney outcomes following childhood acute kidney injury receiving dialysis: A population-based cohort study,”3 and for providing thoughtful feedback. The letter from Zhao et al.1 correctly highlights that outcomes after AKI differ significantly depending on the cause of AKI.
Authors’ Reply
cardiovascular disease hemodialysis randomized controlled trials renal transplantation cardiovascular events Reliable data on reversal of oral factor Xa inhibitors at the time of transplant surgery are lacking. Andexanet alfa, a recombinant variant of human factor Xa, efficiently reduced anti–factor Xa activity in patients with acute major bleeding,1 but no data exist in the setting of urgent transplant surgery.
Authors’ Reply
transplantation histopathology survival rejection acute allograft rejection chronic allograft rejection We thank Matas et al.
Authors’ Reply
cardiovascular disease hemodialysis randomized controlled trials renal transplantation cardiovascular events Reliable data on reversal of oral factor Xa inhibitors at the time of transplant surgery are lacking. Andexanet alfa, a recombinant variant of human factor Xa, efficiently reduced anti–factor Xa activity in patients with acute major bleeding,1 but no data exist in the setting of urgent transplant surgery.
Authors’ Reply
transplantation histopathology survival rejection acute allograft rejection chronic allograft rejection We thank Matas et al.
Authors’ Reply
tenapanor hyperphosphatemia phosphate binders dialysis phosphate uptake We thank Dr. Kulkarni for the insightful comments about our manuscript.
Authors’ Reply
anemia chronic kidney disease erythropoietin We thank Eleftheriadis et al.1 for their attention to our manuscript, “Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study,”2 and their letter on the potential effects of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors on adaptive immunity. We support basic scientific research to explore various aspects of HIF biology.
Authors’ Reply
epidemiology and outcomes kidney transplantation kidney biopsy Husain and Mohan request clarification about our cohort study of biopsies to determine organ quality during kidney allocation.1 Many donated kidneys in the United States undergo biopsy, and abnormal histology is a leading reason for subsequent organ discard. Fortunately, international variation in organ allocation offers a tremendous opportunity to determine whether practices, such as donor kidney biopsy, add value.
Authors’ Reply
epidemiology and outcomes kidney transplantation kidney biopsy Husain and Mohan request clarification about our cohort study of biopsies to determine organ quality during kidney allocation.1 Many donated kidneys in the United States undergo biopsy, and abnormal histology is a leading reason for subsequent organ discard. Fortunately, international variation in organ allocation offers a tremendous opportunity to determine whether practices, such as donor kidney biopsy, add value.
Authors’ Reply
anemia chronic kidney disease erythropoietin We thank Eleftheriadis et al.1 for their attention to our manuscript, “Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study,”2 and their letter on the potential effects of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors on adaptive immunity. We support basic scientific research to explore various aspects of HIF biology.
Authors’ Reply
chronic kidney disease hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trial hemodialysis In a letter to the editor regarding the recently published article titled “Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan,”1 Liu et al.2 note that our manuscript does not provide information regarding the primary cause of CKD (i.e., CKD etiology) in our patient population...
Authors’ Reply
chronic kidney disease hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trial hemodialysis In a letter to the editor regarding the recently published article titled “Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan,”1 Liu et al.2 note that our manuscript does not provide information regarding the primary cause of CKD (i.e., CKD etiology) in our patient population...
Authors’ Reply
nephron renal morphology glomerulus We thank Seibel and colleagues1 for their thoughtful letter on the importance of nephron number. We agree that nephron number warrants investigation as a prognostic marker in the kidney cancer population. However, we would also argue that glomerular density should not be simply viewed as a surrogate for nephron number.
Authors’ Reply
acute renal failure COVID-19 In their letter, Gevers and colleagues1 highlight concerns that remdesivir and its metabolite, GS-441524, may carry a risk of toxicity to the renal tubular epithelium, and that risks may be more considerable for patients with predialysis CKD. We agree that the potential risks of remdesivir and the concern for nephrotoxicity are likely greater in patients with predialysis CKD who have an eGFR of <30 ml/min per 1.73 m2 compared with patients receiving dialysis.
Authors’ Reply
acute renal failure COVID-19 In their letter, Gevers and colleagues1 highlight concerns that remdesivir and its metabolite, GS-441524, may carry a risk of toxicity to the renal tubular epithelium, and that risks may be more considerable for patients with predialysis CKD. We agree that the potential risks of remdesivir and the concern for nephrotoxicity are likely greater in patients with predialysis CKD who have an eGFR of <30 ml/min per 1.73 m2 compared with patients receiving dialysis.
Authors’ Reply
COVID AKI COVID-19 Zijlstra et al.1 question whether delay to postmortem biopsy and ensuing tissue autolysis could have interfered with our molecular diagnostics. They ask how long after death were biopsies done in our study, and suggest that studies using more rapid postmortem biopsy might be more productive. Supplemental Table 1, included in our paper,2 provided the times between death and biopsy. Out of 12 cases, 11 were biopsied within 24 hours postmortem; three were performed within 2.5 hours.
Authors’ Reply
When you create an account, you will be asked for your name, email address and other information. Just like commercial web sites, we do need details from you in order to complete your purchase of an article. Select the "Create an Account" link to create your account. You will then be asked to register a user name, email address and you will need to create a password that is at least eight characters in length.
Authors’ Reply
chronic kidney disease Gupta and Burns1 propose the null association between baseline eGFR <60 ml/min per 1.73 m2 and risk for dementia in SPRINT may be attributable to the diminished predictive power of a single eGFR measurement in a population at high vascular risk. Due to the bidirectional relation between kidney disease and vascular disease, disentangling their respective contributions to the development of cognitive impairment is challenging in observational studies.
AUTHORS’ REPLY
Daniela Mazzaccaro Daniela Mazzaccaro Correspondence Corresponding author: Daniela Mazzaccaro, Operative Unit of Vascular Surgery, IRCCS Policlinico San Donato, Piazza Malan,1 – 20097 San Donato Milanese (MI) – Italy +390252774341 Affiliations Operative Unit of Vascular Surgery, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy Search for articles by this author Federico Ambrogi Valentina Milani Alfredo Modafferi Massimiliano Maria Marrocco-Trischitta Massimiliano Maria...
Authors’ Reply
chronic kidney disease hemodialysis hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trials The following is in response to a letter to the editor submitted by Tanaka et al. concerning the recently published article titled “Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.”1 In their letter, Tanaka et al.
Authors’ Reply
glomerular filtration rate To address the question raised by Dr. Rutkowski,1 we performed a post hoc analysis examining how often Black patients with an eGFR of 30–44 ml/min per 1.73 m2, calculated using the CKD–Epidemiology Collaboration (CKD-EPI) equation, who were prescribed metformin, would have been reclassified as having an eGFR <30 ml/min per 1.73 m2 if GFR were estimated using the CKD-EPI equation without the race coefficient.
Authors’ Reply
rationing We agree that there are limitations to the use of Sequential Organ Failure Assessment (SOFA) scores for stratification of mortality risk of patients with CKD and ESKD.1 Using a single creatinine (or daily urine volume) measurement to assess the kidney function of patients with CKD is one of many limitations of SOFA scores, as is the lack of differentiation in the SOFA score between acute kidney disease and CKD.
Authors’ Reply
chronic kidney disease hemodialysis hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trials The following is in response to a letter to the editor submitted by Tanaka et al. concerning the recently published article titled “Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.”1 In their letter, Tanaka et al.
Authors’ Reply
COVID-19 SARS-CoV-2 acute kidney failure autopsy electron microscopy We acknowledge the expertise of the letter writers and appreciate their critical comments. We agree with Delsante et al.1 that there are weaknesses to each modality of detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in autopsy kidneys.
Authors’ Reply
covid-19 acute renal failure ace2 soluble ACE2 AKI ACE inhibitors Angiotensin II receptor blockers In our Perspective article, we aimed to discuss the emerging mechanisms that might be involved in the pathophysiology of coronavirus disease 2019 (COVID-19)–associated AKI and emphasized the need for more information. At the time of writing, data were largely limited to the two studies from China reporting data from autopsies.
Authors’ Reply
kidney transplantation albuminuria proteinuria We thank Jehn et al.1 for their interest in our paper2 and their application of our equations to kidney transplant recipients and living donors.
Authors’ Reply
covid-19 acute renal failure ace2 soluble ACE2 AKI ACE inhibitors Angiotensin II receptor blockers In our Perspective article, we aimed to discuss the emerging mechanisms that might be involved in the pathophysiology of coronavirus disease 2019 (COVID-19)–associated AKI and emphasized the need for more information. At the time of writing, data were largely limited to the two studies from China reporting data from autopsies.
Authors’ Reply
We thank Preka et al. for their comments regarding our analysis using the US Renal Data System to investigate the association between higher versus lower eGFR at dialysis initiation in children and survival.[1][1] We concur that postponing chronic dialysis in children in every clinical setting would
Authors’ Reply
Authors’ Reply Germaine Wong, Richard L. Hope, Kirsten Howard, Jeremy R. Chapman, Antoni Castells, Simon D. Roger, Michael J. Bourke, Petra Macaskill, Robin Turner, Gabrielle Williams, Wai H. Lim, Charmaine E. Lok, Fritz Diekman, Nicholas Cross, Shaundeep Sen, Richard D.M. Allen, Steven J. Chadban, Carol A. Pollock, Allison Tong, Armando Teixeira-Pinto, Jean Y.H. Yang, Narelle Williams, Eric Au, Anh Kieu, Laura James, Jonathan C. Craig JASN Nov 2019, 30 (11) 2276-2277; DOI: 10.1681/ASN.2019090889
Authors’ Reply
We thank Rostoker et al.1 for their comment on our paper.2 We acknowledge that our database lacks several clinical factors that may relate to the patients’ prognoses, including those pointed out by Rostoker et al. Like any other observational studies, our analysis was also subject to unknown confounders. Although randomization is an ideal method to control for confounding, we took an alternative approach—an instrumental variable (IV) analysis—that can deal with even unmeasured confounders.
Authors’ Reply
transplantation Epidemiology and outcomes depression We thank Moulton et al.1 for the valuable comments. We carefully considered practice effects when designing our study,2 and improvements in cognitive function cannot be attributed to retest effects alone.
Authors’ Reply
hemodialysis SSRIs depression safety sudden cardiac death We thank Chilcot and Farrington1 for their interest in our paper2 and thoughtful comments surrounding the treatment of depression in hemodialysis patients. We agree with the letter writers that our observational study was not designed to evaluate the effect of antidepressant pharmacotherapy (versus no treatment) on mortality among individuals with hemodialysis-dependent ESRD.
Authors’ Reply
dialysis survival confounding Veterans Health Administration comparative analysis We appreciate Dr. Yan’s letter1 and interest in our article.2 We agree on the importance of accounting for differences in survival by race and age, especially in the dialysis population. As noted, these potential confounders are included in our adjusted models to evaluate the average effect of dialysis setting on survival (the main goal of our analysis).
Authors’ Reply
We appreciate the comments of the authors regarding the fact that sudden cardiac arrest is a highly lethal condition. Per previous reports, only half of patients who suffer a cardiac arrest in dialysis clinics survive to hospital admission and only one quarter survive to hospital discharge, a point
Authors’ Reply
We thank Tabibzadeh et al. for their comments. We agree that bisphosphonates are safe and the fear of adynamic bone disease should not be a reason to preclude its use in kidney transplant recipients.
Authors’ Reply
We thank Ferenbach and colleagues for this important comment on the biases introduced by different single-cell dissociation methods during the single-cell RNA sequencing (scRNA-seq) workflow. An ideal dissociation protocol would generate a cell suspension that accurately reflects the abundance of
Authors’ Reply
We thank Lifschitz[1][1] for a valuable comment on our work. It is true that renal sympathetic nerve activity has not been directly measured in humans during isometric exercise, and therefore, the measured decrease in renal blood flow may in theory be caused by circulating vasoactive substances,
Authors’ Reply
We thank Kousios et al. [1][1] for their comments on monoclonal Ig-associated renal diseases in the setting of smoldering multiple myeloma (SMM). In their letter, they express concern that a diagnostic gap may be created if such patients are excluded from monoclonal gammopathy of renal
Authors’ Reply
We thank Weinhandl[1][1] for his comments regarding our analyses using the US Renal Data System of the association between gabapentin and pregabalin use and adverse outcomes among patients on hemodialysis.[2][2] We acknowledge that we were limited in our ability to reliably capture benzodiazepine
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with S’
Contact S’, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack